News|Articles|November 18, 2026

Exploratory Insights into Early Tolerability and Treatment Experience with VYLOY® (zolbetuximab-clzb) in SPOTLIGHT and GLOW

Sponsored Content by Astellas Pharma US, Inc.

Authored by Cassandra Matney, MD, US Medical Affairs at Astellas Pharma

Locally advanced, unresectable or metastatic gastric and gastroesophageal junction (G/GEJ) adenocarcinoma remains a difficult disease to manage, where biomarker testing increasingly shapes treatment decisions. For patients with human epidermal growth factor receptor 2 (HER2)-negative advanced, unresectable disease, biomarker testing is playing an increasingly important role in informing treatment decisions.

Claudin 18.2 (CLDN18.2) is a highly prevalent biomarker in this setting in advanced G/GEJ cancer.1-11 It is estimated to be present in more than a third (38%) of patients with advanced disease.1,2

VYLOY® (zolbetuximab-clzb) plus fluoropyrimidine- and platinum-containing chemotherapy is approved 1L for the treatment of adults with locally advanced unresectable or metastatic CLDN18.2-positive, HER2-negative G/GEJ adenocarcinoma. This combination is the only NCCN Category 1, Preferred first-line CLDN18.2-directed treatment option in this setting. The chemotherapy backbone recommended in the Guidelines is fluoropyrimidine and oxaliplatin.*12,13 Data with VYLOY continues to grow with information that may support clinical-decision making. Recently, an ad hoc censoring analysis was published that explored the impact of both inadequate dose exposure and discontinuing treatment early due to nausea and vomiting had on outcomes. It also included insights on effective proactive strategies to manage nausea and vomiting.15

The Warnings & Precautions (W&P) for VYLOY include hypersensitivity reactions, including serious anaphylaxis reactions, and serious and fatal infusion-related reactions and severe nausea and vomiting. See below for additional information about these W&Ps and most common adverse reactions, as well as further discussion of nausea and vomiting throughout this article.

Establishing Efficacy and Safety Through SPOTLIGHT and GLOW

VYLOY in combination with chemotherapy was evaluated in two Phase 3 global trials, SPOTLIGHT (NCT03504397), evaluating VYLOY plus mFOLFOX6 (n=283) or placebo plus mFOLFOX6 (n=282) and GLOW (NCT03653507), evaluating VYLOY plus CAPOX (n=254) or placebo plus CAPOX (n=253).14 In both SPOTLIGHT and GLOW, with over 1,000 participants across both trials, treatment with VYLOY plus chemotherapy demonstrated statistically significant improvements in progression‑free survival and overall survival. These studies established the efficacy and safety profile of VYLOY in a biomarker‑defined population as seen in the full prescribing information.14

SPOTLIGHT demonstrated significant improvement in median progression-free survival (PFS) of 10.6 months (95% confidence interval [CI]; 8.9-12.5) when treated with VYLOY plus mFOLFOX6 and 8.7 months (95% CI; 8.2-10.3) when treated with placebo and mFOLFOX6.14 The study also demonstrated significant improvement in median overall survival (OS) of 18.2 months (95% CI; 16.4-22.9) and 15.5 months (95% CI; 13.5-16.5) respectively. Treatment with VYLOY plus mFOLFOX6 resulted in a 25% reduction in risk of progression or death (HR=0.75 [95% CI ; 0.60-0.94]; P=0.0066) and a 25% reduction in the risk of death (HR=0.75 [95% CI: 0.60-0.94]; P=0.0053).14

In the SPOTLIGHT trial, in patients that received at least one dose of VYLOY, serious adverse reactions occurred in 45% of patients treated with VYLOY in combination with mFOLFOX6; the most common serious adverse reactions (≥2%) were vomiting (8%), nausea (7%), neutropenia (2.9%), febrile neutropenia (2.9%), diarrhea (2.9%), intestinal obstruction (3.2%), pyrexia (2.5%), pneumonia (2.5%), respiratory failure (2.2%), pulmonary embolism (2.2%), decreased appetite (2.1%) and sepsis (2.0%).14 Fatal adverse reactions occurred in 5% of patients who received VYLOY in combination with mFOLFOX6 including sepsis (1.4%), pneumonia (1.1%), respiratory failure (1.1%), intestinal obstruction (0.7%), acute hepatic failure (0.4%), acute myocardial infarction (0.4%), death (0.4%), disseminated intravascular coagulation (0.4%), encephalopathy (0.4%), and upper gastrointestinal hemorrhage (0.4%).14 Permanent discontinuation of VYLOY due to an adverse reaction occurred in 20% of patients; the most common adverse reactions leading to discontinuation (≥2%) were nausea and vomiting.14 Dosage interruptions of VYLOY due to an adverse reaction occurred in 75% of patients; the most common adverse reactions leading to dose interruption (≥5%) were nausea, vomiting, neutropenia, abdominal pain, fatigue, and hypertension.14

GLOW demonstrated statistically significant improvement in median PFS of 8.2 months (95% CI; 7.5-8.8) when treated with VYLOY plus CAPOX and 6.8 months (95% CI; 6.1-8.1) when treated with placebo and CAPOX.14 The study also showed statistically significant improvement in median OS of 14.4 months (95% CI; 12.3-16.5) and 12.2 months (95% CI; 10.3-13.7), respectively.14 When treated with VYLOY plus CAPOX, patients saw a 31% reduction in risk of progression or death (HR=0.69 [95% CI: 0.54-0.87]; P=0.0007) and a 23% reduction in the risk of death (HR=0.77 [95% CI: 0.62-0.97]; P=0.0118).14

In the GLOW trial, in patients that received at least one dose of VYLOY, serious adverse reactions occurred in 47% of patients treated with VYLOY in combination with CAPOX; the most common serious adverse reactions (≥2%) were vomiting (6%), nausea (4.3%), decreased appetite (3.9%), decreased platelet count (3.1%), upper gastrointestinal hemorrhage (2.8%), diarrhea (2.8%), pneumonia (2.4%), pulmonary embolism (2.3%), and pyrexia (2.0%).14 Fatal adverse reactions occurred in 8% of patients who received VYLOY in combination with CAPOX including sepsis (1.2%), pneumonia (0.4%), death (0.8%), upper gastrointestinal hemorrhage (0.8%), cerebral hemorrhage (0.8%), abdominal infection (0.4%), acute respiratory distress syndrome (0.4%), cardio-respiratory arrest (0.4%), decreased platelet count (0.4%), disseminated intravascular coagulation (0.4%), dyspnea (0.4%), gastric perforation (0.4%), hemorrhagic ascites (0.4%), procedural complication (0.4%), sudden death (0.4%), and syncope (0.4%).14

In both trials, nausea and vomiting were the most common and severe adverse reactions with VYLOY plus chemotherapy, warranting further evaluation of treatment exposure and survival.

Proactive Strategies to Manage Nausea and Vomiting are Critical

Across SPOTLIGHT and GLOW, nausea and vomiting occurred more often in the first cycle of treatment and early in the first infusion, often within the first hour after starting the VYLOY infusion.14-15 Median time to the first occurrence of nausea/vomiting on cycle 1, day 1 was 50.5 minutes after the start of the first infusion (range 0-371 minutes, n=90).15 Median time to onset was evaluated among patients who experienced nausea/vomiting and for whom time-of-onset data were available.15 On infusion Day 1, nausea and/or vomiting events were predominantly Grade 1–2. On infusion Day 2, approximately 1% of patients experienced Grade 3 nausea or vomiting.15 Notably, across grades, the incidence of nausea declined by nearly 50% on the first to the second infusion day, with continued decreases observed with subsequent cycles.15 While the results in the graph below are observational in nature, they help support in clinic expectations when initiating therapy with VYLOY, specific to nausea and vomiting.

The National Comprehensive Cancer Network® (NCCN®) classifies zolbetuximab-clzb (VYLOY) as highly emetogenic and recommends premedication with a preferred four-drug antiemetic regimen that includes a steroid.16 Exploratory, observational findings from the post hoc analysis on SPOTLIGHT and GLOW to manage nausea and vomiting are consistent with the NCCN guidance:

  • Patients who were premedicated with a 3-drug (vs 2 drug) antiemetic regimen experienced a lower incidence of nausea and vomiting
    • 3-drug regimen: 60.8% experienced no nausea and 75.3% no vomiting15
    • 2-drug regimen: 51.4% experienced no nausea and 58.9% no vomiting15
  • Including steroids in the prophylactic antiemetic regimen led to less nausea and vomiting
    • Patients who were given steroids at first infusion: 57.9% experienced no nausea and 63.7% no vomiting15
    • Patients who were not given steroids: 49.7% experienced no nausea and 62.6% no vomiting15

Per the VYLOY full prescribing information, slower infusion rates and/or infusion interruptions can be additional prevention and mitigation techniques in the management of nausea and vomiting.14

An Ad Hoc Analysis Explored Dose Exposure and Survival

This is an exploratory, post hoc analysis that was not prespecified in the statistical analysis plan. No formal hypothesis testing was performed, and no P values were reported. Results are descriptive and hypothesis-generating only.15

To better understand the impact of nausea and vomiting, along with reduced VYLOY exposure, the ad hoc analysis assessed PFS and OS after censoring the 9.9% of patients (53/537) in the VYLOY plus chemotherapy arm who had inadequate dose exposure or discontinued early due to these adverse events, versus 0.6% (3/535) in the placebo arm across the Phase 3 trials of SPOTLIGHT and GLOW combined.15

Patients were censored due to experiencing inadequate dose exposure (dose interruption of any study drug with <75% relative exposure intensity of VYLOY or placebo) or discontinuing early treatment (withdrawal of any study drug with VYLOY or placebo within 63 days) due to nausea and vomiting.15

In the exploratory, post-hoc analysis of SPOTLIGHT, patients treated with VYLOY plus mFOLFOX6 (n=283) observed a median PFS of 12.4 months (95% CI; 10.4-16.7) and 8.9 months when treated with placebo plus mFOLFOX6 (n=282) (95% CI; 8.2-10.4).17 This ad hoc analysis was performed on prespecified landmark analyses and included an additional ~1 year of follow-up beyond the primary analysis, for which the cutoff date was September 2022, compared with September 2023 for the exploratory ad hoc analysis.1,18

In this same post-hoc analysis, patients treated with VYLOY plus mFOLFOX6 observed a median OS of 20.7 months (95% CI; 18.2-23.8) and 15.6 months (95% CI; 13.7-16.9) when treated with placebo plus mFOLFOX6.17

In the exploratory, post-hoc analysis of GLOW, patients treated with VYLOY plus CAPOX (n=254) observed a median PFS of 8.3 months (95% CI; 7.9-9.2) and 7.2 months (95% CI; 6.2-8.1) when treated with placebo plus CAPOX (n=253).17 Treatment with VYLOY plus CAPOX observed a median OS of 15.3 months (95% CI; 13.1-17.8) and 12.2 months (95% CI; 10.5-13.9) when treated with the placebo plus CAPOX.17 This ad hoc analysis was performed on prespecified landmark analyses and included an additional ~1 year of follow-up beyond the primary analysis, for which the cutoff date was October 2022, compared with January 2024 for the exploratory ad hoc analysis.2,18

In summary, patients who did not experience early treatment discontinuation or inadequate dose exposure due to nausea and vomiting were observed to have numerically longer PFS and OS. These findings are hypothesis‑generating only and do not establish a causal relationship between treatment exposure, management strategies, and clinical outcomes.

Because these analyses involved post hoc censoring and were not prespecified, the results should be interpreted with caution and cannot be used to draw conclusions regarding treatment optimization or outcome modification.

Proactive Management: Getting Ahead of the First Infusion

The early-onset, earlier-cycles nature of nausea and vomiting with VYLOY has direct implications for how clinicians approach treatment initiation. Before the first infusion, patients benefit from clear communication that nausea and vomiting are most likely to occur early in treatment and it was observed that it may decrease with subsequent infusion cycles of VYLOY, setting realistic expectations that support informed engagement with the treatment plan.14

Proactive antiemetic management, aligned with NCCN guidance and the zolbetuximab-clzb (VYLOY) Prescribing Information, plays an important role in clinical practice, particularly given the early timing of nausea and vomiting observed in zolbetuximab-clzb (VYLOY)‑treated patients.16 Clinicians should consult the complete Prescribing Information for guidance on antiemetic premedication protocols, infusion rate adjustments, dose interruption criteria, and management of other adverse reactions, including hypersensitivity and infusion-related reactions.

Interpreting the Totality of Evidence

For patients with CLDN18.2, HER2-negative advanced G/GEJ cancer who have historically faced limited targeted therapy options, VYLOY represents a meaningful treatment option. The exploratory ad hoc analyses build on that foundation with descriptive, hypothesis-generating insights of its tolerability profile and potential relationship to dose exposure and outcomes. Taken together, this evidence underscores a consistent clinical message: proactive, guideline-aligned antiemetic management from the start of treatment is a critical component of care.

Healthcare professionals may refer to www.vyloyhcp.com for the complete Prescribing Information, full analysis results and additional educational resources.

*Category 1: Based upon high-level evidence (≥1 randomized Phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate. Preferred intervention: Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.12,13

INDICATION & IMPORTANT SAFETY INFORMATION

VYLOY® (zolbetuximab-clzb), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.

WARNINGS AND PRECAUTIONS

Hypersensitivity reactions, including serious anaphylaxis reactions, and serious and fatal infusion-related reactions (IRR) have been reported in clinical studies when VYLOY has been administered. Any grade hypersensitivity reactions, including anaphylactic reactions, occurring with VYLOY in combination with mFOLFOX6 or CAPOX was 18%. Severe (Grade 3 or 4) hypersensitivity reactions, including anaphylactic reactions, occurred in 2% of patients. Seven patients (1.3%) permanently discontinued VYLOY for hypersensitivity reactions, including two patients (0.4%) who permanently discontinued VYLOY due to anaphylactic reactions. Seventeen (3.2%) patients required dose interruption, and three patients (0.6%) required infusion rate reduction due to hypersensitivity reactions. All grade IRRs occurred in 3.2% in patients administered VYLOY in combination with mFOLFOX6 or CAPOX. Severe (Grade 3) IRRs occurred in 2 (0.4%) patients who received VYLOY. An IRR led to permanent discontinuation of VYLOY in 2 (0.4%) patients and dose interruption in 7 (1.3%) patients. The infusion rate was reduced for VYLOY for 2 (0.4%) patients due to an IRR. Monitor patients during infusion with VYLOY and for 2 hours after completion of infusion or longer if clinically indicated, for hypersensitivity reactions with symptoms and signs that are highly suggestive of anaphylaxis (urticaria, repetitive cough, wheeze and throat tightness/change in voice). Monitor patients for signs and symptoms of IRRs including nausea, vomiting, abdominal pain, salivary hypersecretion, pyrexia, chest discomfort, chills, back pain, cough and hypertension. If a severe or life-threatening hypersensitivity or IRR reaction occurs, discontinue VYLOY permanently, treat symptoms according to standard medical care, and monitor until symptoms resolve. For any Grade 2 hypersensitivity or IRR, interrupt the VYLOY infusion until Grade ≤1, then resume at a reduced infusion rate for the remaining infusion. Follow Grade 2 management for Grade 3 infusion-related nausea and vomiting. Premedicate the patient with antihistamines for the subsequent infusions, and closely monitor the patient for symptoms and signs of a hypersensitivity reaction. The infusion rate may be gradually increased as tolerated.

Severe Nausea and Vomiting. VYLOY is emetogenic. Nausea and vomiting occurred more often during the first cycle of treatment. All grade nausea and vomiting occurred in 82% and 67% respectively of patients treated with VYLOY in combination with mFOLFOX6 and 69% and 66% in combination with CAPOX, respectively. Severe (Grade 3) nausea occurred in 16% and 9% of patients treated with VYLOY in combination with mFOLFOX6 or CAPOX respectively. Severe (Grade 3) vomiting occurred in 16% and 12% of patients treated with VYLOY in combination with mFOLFOX6 or CAPOX. Nausea led to permanent discontinuation of VYLOY in combination with mFOLFOX6 or CAPOX in 18 (3.4%) patients and dose interruption in 147 (28%) patients. Vomiting led to permanent discontinuation of VYLOY in combination with mFOLFOX6 or CAPOX in 20 (3.8%) patients and dose interruption in 150 (28%) patients. Pretreat with antiemetics prior to each infusion of VYLOY. Manage patients during and after infusion with antiemetics or fluid replacement. Interrupt the infusion, or permanently discontinue VYLOY based on severity.

ADVERSE REACTIONS

Most common adverse reactions (≥15%): Nausea, vomiting, fatigue, decreased appetite, diarrhea, peripheral sensory neuropathy, abdominal pain, constipation, decreased weight, hypersensitivity reactions, and pyrexia.

Most common laboratory abnormalities (≥15%): Decreased neutrophil count, decreased leucocyte count, decreased albumin, increased creatinine, decreased hemoglobin, increased glucose, decreased lymphocyte count, increased aspartate aminotransferase, decreased platelets, increased alkaline phosphatase, increased alanine aminotransferase, decreased glucose, decreased sodium, decreased phosphate, decreased potassium, and decreased magnesium.

SPOTLIGHT Study: 279 patients with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma whose tumors were CLDN18.2 positive who received at least one dose of VYLOY in combination with mFOLFOX6

Serious adverse reactions occurred in 45% of patients treated with VYLOY in combination with mFOLFOX6; the most common serious adverse reactions (≥2%) were vomiting (8%), nausea (7%), neutropenia (2.9%), febrile neutropenia (2.9%), diarrhea (2.9%), intestinal obstruction (3.2%), pyrexia (2.5%), pneumonia (2.5%), respiratory failure (2.2%), pulmonary embolism (2.2%), decreased appetite (2.1%) and sepsis (2.0%). Fatal adverse reactions occurred in 5% of patients who received VYLOY in combination with mFOLFOX6 including sepsis (1.4%), pneumonia (1.1%), respiratory failure (1.1%), intestinal obstruction (0.7%), acute hepatic failure (0.4%), acute myocardial infarction (0.4%), death (0.4%), disseminated intravascular coagulation (0.4%), encephalopathy (0.4%), and upper gastrointestinal hemorrhage (0.4%). Permanent discontinuation of VYLOY due to an adverse reaction occurred in 20% of patients; the most common adverse reactions leading to discontinuation (≥2%) were nausea and vomiting. Dosage interruptions of VYLOY due to an adverse reaction occurred in 75% of patients; the most common adverse reactions leading to dose interruption (≥5%) were nausea, vomiting, neutropenia, abdominal pain, fatigue, and hypertension.

GLOW Study: 254 patients with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma whose tumors were CLDN18.2 positive who received at least one dose of VYLOY in combination with CAPOX

Serious adverse reactions occurred in 47% of patients treated with VYLOY in combination with CAPOX; the most common serious adverse reactions (≥2%) were vomiting (6%), nausea (4.3%), decreased appetite (3.9%), decreased platelet count (3.1%), upper gastrointestinal hemorrhage (2.8%), diarrhea (2.8%), pneumonia (2.4%), pulmonary embolism (2.3%), and pyrexia (2.0%). Fatal adverse reactions occurred in 8% of patients who received VYLOY in combination with CAPOX including sepsis (1.2%), pneumonia (0.4%), death (0.8%), upper gastrointestinal hemorrhage (0.8%), cerebral hemorrhage (0.8%), abdominal infection (0.4%), acute respiratory distress syndrome (0.4%), cardio-respiratory arrest (0.4%), decreased platelet count (0.4%), disseminated intravascular coagulation (0.4%), dyspnea (0.4%), gastric perforation (0.4%), hemorrhagic ascites (0.4%), procedural complication (0.4%), sudden death (0.4%), and syncope (0.4%). Permanent discontinuation of VYLOY due to an adverse reaction occurred in 19% of patients; the most common adverse reaction leading to discontinuation (≥2%) was vomiting. Dosage interruption of VYLOY due to an adverse reaction occurred in 55% of patients; the most common adverse reactions leading to dose interruption (≥2%) were nausea, vomiting, neutropenia, thrombocytopenia, anemia, fatigue, infusion-related reaction, and abdominal pain.

POST MARKETING EXPERIENCE:

Gastrointestinal disorders: gastritis, protein-losing gastroenteropathy adverse reactions have been identified during post-approval use of VYLOY. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

SPECIFIC POPULATIONS

Lactation Advise lactating women not to breastfeed during treatment with VYLOY and for 8 months after the last dose.

Please click here for accompanying Full Prescribing Information for VYLOY (zolbetuximab-clzb).

References

  1. Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655-1668. Errata in: Lancet. 2023;402(10398):290; Lancet. 2024;403(10421):30.
  2. Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133-2141.
  3. Fuchs CS, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated PD L1 positive advanced gastric or gastroesophageal junction cancer: 2 year update of the randomized phase 3 KEYNOTE 061 trial. Gastric Cancer. 2022;25(1):197-206.
  4. Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-484.
  5. Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. Ann Oncol. 2012;23(10):2656-2662.
  6. Kim WH, Gomez-Izquierdo L, Vilardell F, et al. HER2 status in gastric and gastroesophageal junction cancer: results of the large, multinational HER-EAGLE study. Appl Immunohistochem Mol Morphol. 2018;26(4):239-245.
  7. Schoemig-Markiefka B, Eschbach J, Scheel AH, et al. Optimized PD-L1 scoring of gastric cancer. Gastric Cancer. 2021;24(5):1115-1122.
  8. Mehta R, Liepa AM, Zheng S, Chatterjee A. Real-world molecular biomarker testing patterns and results for advanced gastroesophageal cancers in the United States. Curr Oncol. 2023;30(2):1869-1881.
  9. Shitara K, Ajani J, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942-948.
  10. Rha SY, Oh D-Y, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181-1195.
  11. Chao J, Fuchs CS, Shitara K, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7(6):895-902.
  12. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastric Cancer V.4.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed September 16, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  13. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.4.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed September 16, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  14. VYLOY. Package insert. Northbrook, IL: Astellas Pharma US, Inc; 2026.
  15. Shitara K, Smyth E, Lordick F, et al. Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies [published online January 7, 2026]. ESMO Open. 2026. Accessed January 27, 2026. https://www.esmoopen.com/action/showPdf?pii=S2059-7029%2825%2901801-0.
  16. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis V.2.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed June 24, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  17. Supplement to: Shitara K, Smyth E, Lordick F, et al. Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies [published online January 7, 2026]. ESMO Open. 2026. Accessed January 27, 2026. https://www.esmoopen.com/action/showPdf?pii=S2059-7029%2825%2901801-0.
  18. Supplement to: Shitara K, Shah MA, Lordick F, et al. Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N Engl J Med. 2024;391(12):1159-1162.

©2026 Astellas Pharma Inc. or its affiliates. All trademarks are the property of their respective owners.

MAT-US-VYL-2026-00078 09/2026


Related to this article